ARKG vs BIL

ARK Genomic Revolution ETF vs SPDR Bloomberg 1-3 Month T-Bill ETF

Quick take
  • BIL has the lower expense ratio at 0.14% vs 0.75% for ARKG.
  • BIL pays a higher dividend yield (3.85%).

Side-by-side metrics

MetricARKGBIL
Expense ratio
Annual fee. Lower is better.
0.75%0.14%
Dividend yield
Trailing 12-month yield.
0.00%3.85%
AUM
Assets under management — bigger funds are typically more liquid.
$1.73B$47.08B
YTD return
44.53%1.83%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.380.00
P/E ratio
Last price
$43.17$91.47
Inception
Issuer
ARKState Street

ARKG top holdings

Top holdings · ARKG
TWSTTwist Bioscience Corp9.15%
TEMTempus AI Inc Class A common stock7.64%
ABSIAbsci Corp7.01%
TXG10x Genomics Inc Ordinary Shares - Class A7.00%
CRSPCRISPR Therapeutics AG6.56%
PSNLPersonalis Inc6.19%
BEAMBeam Therapeutics Inc4.34%
GHGuardant Health Inc4.28%
NTRANatera Inc4.11%
ILMNIllumina Inc3.98%
Sector breakdown · ARKG
Healthcare100.0%

BIL top holdings

Holdings data unavailable for BIL.

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About BIL

BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) is Ultra-short T-Bills, cash-equivalent. Managed by State Street, the fund carries $47.1B in assets under management, an expense ratio of 0.14%, a dividend yield of 3.85%.